Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Misses on Revenue, Stock Down 0.29%

Catalyst Pharmaceuticals reported a loss per share that was better than expected, but the lack of revenue data and guidance may have contributed to a slight decline in stock price. Investors might be concerned about the absence of specific future expectations, which could affect confidence in the company's growth. The stock's reaction of a 0.29% drop reflects these uncertainties.